Cellectis SA (CLLS)
1.87
+0.01
(+0.54%)
USD |
NASDAQ |
Nov 22, 16:00
1.88
+0.01
(+0.53%)
After-Hours: 20:00
Cellectis Cash from Operations (Quarterly): -5.829M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -5.829M |
| June 30, 2024 | 52.18M |
| March 31, 2024 | -23.32M |
| December 31, 2023 | 39.72M |
| September 30, 2023 | -17.09M |
| June 30, 2023 | -19.04M |
| March 31, 2023 | -28.33M |
| December 31, 2022 | -1.22M |
| September 30, 2022 | -26.04M |
| June 30, 2022 | -23.57M |
| March 31, 2022 | -36.61M |
| December 31, 2021 | -21.08M |
| September 30, 2021 | -30.43M |
| June 30, 2021 | -12.12M |
| March 31, 2021 | -40.93M |
| December 31, 2020 | -33.89M |
| September 30, 2020 | -25.61M |
| June 30, 2020 | -22.22M |
| March 31, 2020 | 1.458M |
| December 31, 2019 | -2.882M |
| Date | Value |
|---|---|
| September 30, 2019 | -22.65M |
| June 30, 2019 | -21.22M |
| March 31, 2019 | -22.40M |
| December 31, 2018 | -20.60M |
| September 30, 2018 | -15.01M |
| June 30, 2018 | -12.54M |
| March 31, 2018 | -19.98M |
| December 31, 2017 | -9.513M |
| September 30, 2017 | -15.49M |
| June 30, 2017 | -11.04M |
| March 31, 2017 | -16.28M |
| December 31, 2016 | 1.664M |
| September 30, 2016 | -2.007M |
| June 30, 2016 | -10.16M |
| March 31, 2016 | -22.20M |
| December 31, 2015 | 28.33M |
| September 30, 2015 | -5.235M |
| June 30, 2015 | -18.18M |
| March 31, 2015 | -1.320M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-40.93M
Minimum
Mar 2021
52.18M
Maximum
Jun 2024
-13.84M
Average
-21.65M
Median
Cash from Operations (Quarterly) Benchmarks
| Edap TMS SA | -5.573M |
| Genfit SA | -- |
| DBV Technologies SA | -22.46M |
| Akari Therapeutics PLC | -1.49M |
| Biodexa Pharmaceuticals PLC | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 22.33M |
| Cash from Financing (Quarterly) | -4.218M |
| Free Cash Flow | 60.38M |
| Free Cash Flow Per Share (Quarterly) | -0.0663 |
| Free Cash Flow to Equity (Quarterly) | -8.455M |
| Free Cash Flow to Firm (Quarterly) | -6.634M |
| Free Cash Flow Yield | 36.04% |